title: The protective effect of IFN-gamma in experimental autoimmune diseases: a central role of mycobacterial adjuvant-induced myelopoiesis.
abstract: The study of animal models for organ-specific autoimmune disease contributes to our understanding of human diseases such as multiple sclerosis and rheumatoid arthritis. Although experimental autoimmune diseases develop spontaneously in certain strains of mice, others need to be induced by administration of organ-specific autoantigen, often together with complete Freund's adjuvant (CFA), containing heat-killed mycobacteria. In the two types of models, the role of endogenous interferon-gamma (IFN-gamma) has extensively been investigated by using neutralizing anti-IFN-gamma antibodies and by employing mice genetically deficient in IFN-gamma or its receptor. In these studies disease-promoting as well as disease-protective roles of endogenous IFN-gamma have been described. Remarkably, in most models that rely on the use of CFA, there is abundant evidence for a protective role. Here, we review evidence that this role derives from an inhibitory effect of IFN-gamma on myelopoiesis elicited by the killed mycobacteria. These findings explain the bimodal role of IFN-gamma in different models of autoimmune disease and raise questions regarding the clinical relevance of these models.
authors.affiliation: Laboratory of Immunobiology, Rega Institute, Katholieke Universiteit Leuven, Faculty of Medicine, Belgium. Patrick.Matthys@rega.kuleuven.ac.be
authors.forename: P
authors.initials: P
authors.lastname: Matthys
authors.forename: K
authors.initials: K
authors.lastname: Vermeire
authors.forename: H
authors.initials: H
authors.lastname: Heremans
authors.forename: A
authors.initials: A
authors.lastname: Billiau
mesh_terms: D000818:Animals; D001172:Arthritis, Rheumatoid / Q000276:immunology; D001324:Autoantigens / Q000008:administration & dosage / Q000276:immunology; D001327:Autoimmune Diseases / Q000276:immunology / Q000503:physiopathology*; D004195:Disease Models, Animal; D005620:Freund's Adjuvant / Q000494:pharmacology* / Q000633:toxicity; D006410:Hematopoiesis / Q000187:drug effects*; D006649:Histocompatibility Antigens / Q000276:immunology; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007371:Interferon-gamma / Q000037:antagonists & inhibitors / Q000172:deficiency / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D023421:Models, Animal; D020721:Nervous System Autoimmune Disease, Experimental / Q000276:immunology; D009569:Nitric Oxide / Q000502:physiology; D017471:Receptors, Interferon / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014605:Uveitis / Q000276:immunology; D000096743:Interferon gamma Receptor
chemical_list: D001324:Autoantigens; D005620:Freund's Adjuvant; D006649:Histocompatibility Antigens; D007371:Interferon-gamma; D009569:Nitric Oxide; D017471:Receptors, Interferon; D000096743:Interferon gamma Receptor